A Phase 2, Single-arm, Open-label, Multicenter Study Of The Clinical Activity And Safety Of Enzalutamide In Patients With Advanced, Androgen Receptor-positive, Triple-negative Breast Cancer

Trial Profile

A Phase 2, Single-arm, Open-label, Multicenter Study Of The Clinical Activity And Safety Of Enzalutamide In Patients With Advanced, Androgen Receptor-positive, Triple-negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Medivation; Pfizer
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results of a subgroup analysis assessing overall survival [patients with diagnostic positive (Dx+) breast cancer], presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top